BioCardia CEO Executes Share Purchase Amid Regulatory Milestones and Valuation Questions
BioCardia Inc. CEO Peter Altman purchased 5,400 shares of the company's common stock on July 8, 2026, for a total of $5,208. The transaction occurs as the stock trades significantly below its 52-week high and recent valuation models suggest potential undervaluation. Concurrently, BioCardia has secured regulatory guidance from Japan's Pharmaceutical…